Injectable dendritic cell-carrying alginate gels for immunization and immunotherapy

Biomaterials

Volumn 29, Issue 27, 2008, Pages 3671-3682

  Hori, Yuki ^a   Winans, Amy M ^a   Huang, Catherine C ^a   Horrigan, Elizabeth M ^b   Irvine, Darrell J ^a  

^a Massachusetts Institute of Technology Cambridge   (United States)

^b MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

Author keywords

Alginate; Dendritic cells; Hydrogels; Inflammatory response; Injectable gel

Indexed keywords

ALGINATE; ANTIGENS; CALCIUM; COBALT; COBALT COMPOUNDS; COLLOIDS; COMPUTER NETWORKS; GELATION; HEALTH; HYDROGELS; IMMUNIZATION; MATRIX ALGEBRA; MIXING; NUMERICAL METHODS; POPULATION STATISTICS;

ALGINATE GEL (AG); ALGINATE MATRIX; DENDRITIC CELLS; ELSEVIER (CO); HYDROGEL MATRIX; IMMUNE CELLS; IMMUNE RESPONSES; IN-SITU; IN-VIVO; INFECTIOUS DISEASES; INJECTABLE HYDROGEL; LYMPH NODE (LN); SOLID TUMORS; T CELLS; TIME PERIODS; TRANSFER MODELS;

CELLS;

ALGINIC ACID; DENDRITIC CELL VACCINE; MICROSPHERE; PRONOVA;

ADOPTIVE IMMUNOTHERAPY; ADOPTIVE TRANSFER; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIGEN PRESENTING CELL; ARTICLE; CELLULAR IMMUNITY; CONTROLLED STUDY; DENDRITIC CELL; DRUG DELIVERY SYSTEM; DRUG FORMULATION; HYDROGEL; IMMUNE RESPONSE; IMMUNIZATION; IN VIVO STUDY; INFLAMMATION; INOCULATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE; T LYMPHOCYTE SUBPOPULATION;

ALGINATES; ANIMALS; DENDRITIC CELLS; FLOW CYTOMETRY; GELS; GLUCURONIC ACID; HEXURONIC ACIDS; IMMUNOTHERAPY; MICE; MICE, INBRED C57BL; VACCINES;

MUS;

EID: 46749110694     PISSN: 01429612     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2008.05.033     Document Type: Article

References (60)

1. Banchereau J., Briere F., Caux C., Davoust J., Lebecque S., Liu Y.J., et al. Immunobiology of dendritic cells. Annu Rev Immunol 18 (2000) 767-811
2. Steinman R.M., and Banchereau J. Taking dendritic cells into medicine. Nature 449 7161 (2007) 419-426
3. Nestle F.O., Farkas A., and Conrad C. Dendritic-cell-based therapeutic vaccination against cancer. Curr Opin Immunol 17 2 (2005) 163-169
4. Timmerman J.M., and Levy R. Dendritic cell vaccines for cancer immunotherapy. Annu Rev Med 50 (1999) 507-529
5. Gilboa E. DC-based cancer vaccines. J Clin Invest 117 5 (2007) 1195-1203
6. Lu W., Wu X., Lu Y., Guo W., and Andrieu J.M. Therapeutic dendritic-cell vaccine for simian AIDS. Nat Med 9 1 (2003) 27-32
7. Lee K.H., Wang E., Nielsen M.B., Wunderlich J., Migueles S., Connors M., et al. Increased vaccine-specific T cell frequency after peptide-based vaccination correlates with increased susceptibility to in vitro stimulation but does not lead to tumor regression. J Immunol 163 11 (1999) 6292-6300
8. Rosenberg S.A. Progress in the development of immunotherapy for the treatment of patients with cancer. J Intern Med 250 6 (2001) 462-475
9. Palucka A.K., Ueno H., Fay J.W., and Banchereau J. Taming cancer by inducing immunity via dendritic cells. Immunol Rev 220 (2007) 129-150
10. Chappell D.B., and Restifo N.P. T cell-tumor cell: a fatal interaction?. Cancer Immunol Immunother 47 2 (1998) 65-71
11. Staveley-O'Carroll K., Sotomayor E., Montgomery J., Borrello I., Hwang L., Fein S., et al. Induction of antigen-specific T cell anergy: an early event in the course of tumor progression. Proc Natl Acad Sci U S A 95 3 (1998) 1178-1183
12. Wang H.Y., and Wang R.F. Regulatory T cells and cancer. Curr Opin Immunol 19 2 (2007) 217-223
13. Nagaraj S., Gupta K., Pisarev V., Kinarsky L., Sherman S., Kang L., et al. Altered recognition of antigen is a mechanism of CD8+ T cell tolerance in cancer. Nat Med 13 7 (2007) 828-835
14. Clemente C.G., Mihm Jr. M.C., Bufalino R., Zurrida S., Collini P., and Cascinelli N. Prognostic value of tumor infiltrating lymphocytes in the vertical growth phase of primary cutaneous melanoma. Cancer 77 7 (1996) 1303-1310
15. Mihm Jr. M.C., Clemente C.G., and Cascinelli N. Tumor infiltrating lymphocytes in lymph node melanoma metastases: a histopathologic prognostic indicator and an expression of local immune response. Lab Invest 74 1 (1996) 43-47
16. Onrust S.V., Hartl P.M., Rosen S.D., and Hanahan D. Modulation of l-selectin ligand expression during an immune response accompanying tumorigenesis in transgenic mice. J Clin Invest 97 1 (1996) 54-64
17. Ochsenbein A.F., Klenerman P., Karrer U., Ludewig B., Pericin M., Hengartner H., et al. Immune surveillance against a solid tumor fails because of immunological ignorance. Proc Natl Acad Sci U S A 96 5 (1999) 2233-2238
18. Hermans I.F., Daish A., Yang J., Ritchie D.S., and Ronchese F. Antigen expressed on tumor cells fails to elicit an immune response, even in the presence of increased numbers of tumor-specific cytotoxic T lymphocyte precursors. Cancer Res 58 17 (1998) 3909-3917
19. Speiser D.E., Miranda R., Zakarian A., Bachmann M.F., McKall-Faienza K., Odermatt B., et al. Self antigens expressed by solid tumors do not efficiently stimulate naive or activated T cells: implications for immunotherapy. J Exp Med 186 5 (1997) 645-653
20. Candido K.A., Shimizu K., McLaughlin J.C., Kunkel R., Fuller J.A., Redman B.G., et al. Local administration of dendritic cells inhibits established breast tumor growth: implications for apoptosis-inducing agents. Cancer Res 61 1 (2001) 228-236
21. Melero I., Duarte M., Ruiz J., Sangro B., Galofre J., Mazzolini G., et al. Intratumoral injection of bone-marrow derived dendritic cells engineered to produce interleukin-12 induces complete regression of established murine transplantable colon adenocarcinomas. Gene Ther 6 10 (1999) 1779-1784
22. Nishioka Y., Hirao M., Robbins P.D., Lotze M.T., and Tahara H. Induction of systemic and therapeutic antitumor immunity using intratumoral injection of dendritic cells genetically modified to express interleukin 12. Cancer Res 59 16 (1999) 4035-4041
23. Schrama D., Pedersen L.O., Keikavoussi P., Andersen M.H., Straten Pt P., Brocker E.B., et al. Aggregation of antigen-specific T cells at the inoculation site of mature dendritic cells. J Invest Dermatol 119 6 (2002) 1443-1448
24. Yu P., Lee Y., Liu W., Chin R.K., Wang J., Wang Y., et al. Priming of naive T cells inside tumors leads to eradication of established tumors. Nat Immunol 5 2 (2004) 141-149
25. Sato M., Chamoto K., and Nishimura T. A novel tumor-vaccine cell therapy using bone marrow-derived dendritic cell type 1 and antigen-specific Th1 cells. Int Immunol 15 7 (2003) 837-843
26. Guo Z., Zhang M., Tang H., and Cao X. Fas signal links innate and adaptive immunity by promoting dendritic-cell secretion of CC and CXC chemokines. Blood 106 6 (2005) 2033-2041
27. Ngo V.N., Tang H.L., and Cyster J.G. Epstein-Barr virus-induced molecule 1 ligand chemokine is expressed by dendritic cells in lymphoid tissues and strongly attracts naive T cells and activated B cells. J Exp Med 188 1 (1998) 181-191
28. Sallusto F., Palermo B., Lenig D., Miettinen M., Matikainen S., Julkunen I., et al. Distinct patterns and kinetics of chemokine production regulate dendritic cell function. Eur J Immunol 29 5 (1999) 1617-1625
29. Inaba K., Inaba M., Romani N., Aya H., Deguchi M., Ikehara S., et al. Generation of large numbers of dendritic cells from mouse bone marrow cultures supplemented with granulocyte/macrophage colony-stimulating factor. J Exp Med 176 6 (1992) 1693-1702
30. Stachowiak A.N., Wang Y., Huang Y.C., and Irvine D.J. Homeostatic lymphoid chemokines synergize with adhesion ligands to trigger T and B lymphocyte chemokinesis. J Immunol 177 4 (2006) 2340-2348
31. Friedman R.S., Jacobelli J., and Krummel M.F. Surface-bound chemokines capture and prime T cells for synapse formation. Nat Immunol 7 10 (2006) 1101-1108
32. Proudfoot A.E. The biological relevance of chemokine-proteoglycan interactions. Biochem Soc Trans 34 Pt 3 (2006) 422-426
33. Proudfoot A.E., Handel T.M., Johnson Z., Lau E.K., LiWang P., Clark-Lewis I., et al. Glycosaminoglycan binding and oligomerization are essential for the in vivo activity of certain chemokines. Proc Natl Acad Sci U S A 100 4 (2003) 1885-1890
34. Uchimura K., Morimoto-Tomita M., Bistrup A., Li J., Lyon M., Gallagher J., et al. HSulf-2, an extracellular endoglucosamine-6-sulfatase, selectively mobilizes heparin-bound growth factors and chemokines: effects on VEGF, FGF-1, and SDF-1. BMC Biochem 7 (2006) 2
35. Christopherson II K.W., Campbell J.J., Travers J.B., and Hromas R.A. Low-molecular-weight heparins inhibit CCL21-induced T cell adhesion and migration. J Pharmacol Exp Ther 302 1 (2002) 290-295
36. Eggert A.A., van der Voort R., Torensma R., Moulin V., Boerman O.C., Oyen W.J., et al. Analysis of dendritic cell trafficking using EGFP-transgenic mice. Immunol Lett 89 1 (2003) 17-24
37. Kabashima K., Banks T.A., Ansel K.M., Lu T.T., Ware C.F., and Cyster J.G. Intrinsic lymphotoxin-beta receptor requirement for homeostasis of lymphoid tissue dendritic cells. Immunity 22 4 (2005) 439-450
38. Kamath A.T., Henri S., Battye F., Tough D.F., and Shortman K. Developmental kinetics and lifespan of dendritic cells in mouse lymphoid organs. Blood 100 5 (2002) 1734-1741
39. Eggert A.A., Schreurs M.W., Boerman O.C., Oyen W.J., de Boer A.J., Punt C.J., et al. Biodistribution and vaccine efficiency of murine dendritic cells are dependent on the route of administration. Cancer Res 59 14 (1999) 3340-3345
40. Lappin M.B., Weiss J.M., Delattre V., Mai B., Dittmar H., Maier C., et al. Analysis of mouse dendritic cell migration in vivo upon subcutaneous and intravenous injection. Immunology 98 2 (1999) 181-188
41. Morse M.A., Coleman R.E., Akabani G., Niehaus N., Coleman D., and Lyerly H.K. Migration of human dendritic cells after injection in patients with metastatic malignancies. Cancer Res 59 1 (1999) 56-58
42. Smith A.L., and Fazekas de St Groth B. Antigen-pulsed CD8alpha+ dendritic cells generate an immune response after subcutaneous injection without homing to the draining lymph node. J Exp Med 189 3 (1999) 593-598
43. Andre F., Chaput N., Schartz N.E., Flament C., Aubert N., Bernard J., et al. Exosomes as potent cell-free peptide-based vaccine. I. Dendritic cell-derived exosomes transfer functional MHC class I/peptide complexes to dendritic cells. J Immunol 172 4 (2004) 2126-2136
44. Kaiser A., Donnadieu E., Abastado J.P., Trautmann A., and Nardin A. CC chemokine ligand 19 secreted by mature dendritic cells increases naive T cell scanning behavior and their response to rare cognate antigen. J Immunol 175 4 (2005) 2349-2356
45. Lebre M.C., Burwell T., Vieira P.L., Lora J., Coyle A.J., Kapsenberg M.L., et al. Differential expression of inflammatory chemokines by Th1- and Th2-cell promoting dendritic cells: a role for different mature dendritic cell populations in attracting appropriate effector cells to peripheral sites of inflammation. Immunol Cell Biol 83 5 (2005) 525-535
46. Tang H.L., and Cyster J.G. Chemokine up-regulation and activated T cell attraction by maturing dendritic cells. Science 284 5415 (1999) 819-822
47. Kranz D.M., Tonegawa S., and Eisen H.N. Attachment of an anti-receptor antibody to non-target cells renders them susceptible to lysis by a clone of cytotoxic T lymphocytes. Proc Natl Acad Sci U S A 81 24 (1984) 7922-7926
48. Thomas S. Alginate dressings in surgery and wound management - part 1. J Wound Care 9 2 (2000) 56-60
49. Shang Q., Wang Z., Liu W., Shi Y., Cui L., and Cao Y. Tissue-engineered bone repair of sheep cranial defects with autologous bone marrow stromal cells. J Craniofac Surg 12 6 (2001) 586-593 Discussion 594-5
50. Chang S.C., Rowley J.A., Tobias G., Genes N.G., Roy A.K., Mooney D.J., et al. Injection molding of chondrocyte/alginate constructs in the shape of facial implants. J Biomed Mater Res 55 4 (2001) 503-511
51. Cirone P., Bourgeois J.M., Austin R.C., and Chang P.L. A novel approach to tumor suppression with microencapsulated recombinant cells. Hum Gene Ther 13 10 (2002) 1157-1166
52. Joki T., Machluf M., Atala A., Zhu J., Seyfried N.T., Dunn I.F., et al. Continuous release of endostatin from microencapsulated engineered cells for tumor therapy. Nat Biotechnol 19 1 (2001) 35-39
53. Augst A.D., Kong H.J., and Mooney D.J. Alginate hydrogels as biomaterials. Macromol Biosci 6 8 (2006) 623-633
54. Smetana Jr. K. Cell biology of hydrogels. Biomaterials 14 14 (1993) 1046-1050
55. Friedl P., and Brocker E.B. The biology of cell locomotion within three-dimensional extracellular matrix. Cell Mol Life Sci 57 1 (2000) 41-64
56. Friedl P., Entschladen F., Conrad C., Niggemann B., and Zanker K.S. CD4+ T lymphocytes migrating in three-dimensional collagen lattices lack focal adhesions and utilize beta1 integrin-independent strategies for polarization, interaction with collagen fibers and locomotion. Eur J Immunol 28 8 (1998) 2331-2343
57. Lammermann T., Bader B.L., Monkley S.J., Worbs T., Wedlich-Soldner R., Hirsch K., et al. Rapid leukocyte migration by integrin-independent flowing and squeezing. Nature 453 7191 (2008) 51-55
58. Steinman R.M., and Dhodapkar M. Active immunization against cancer with dendritic cells: the near future. Int J Cancer 94 4 (2001) 459-473
59. Boontheekul T., Kong H.J., and Mooney D.J. Controlling alginate gel degradation utilizing partial oxidation and bimodal molecular weight distribution. Biomaterials 26 15 (2005) 2455-2465
60. Irvine D.J., Stachowiak A.N., and Hori Y. Lymphoid tissue engineering: invoking lymphoid tissue neogenesis in immunotherapy and models of immunity. Semin Immunol 20 2 (2008) 137-146